多年来, researchers at Huntsman Cancer Institute at the 犹他大学 (U of U) have honed a process of developing breast cancer models using tumors donated by breast cancer 病人, which they then implant into mice as a way to study the tumor’s behavior.
Now, the research team reports a new, more efficient way to grow these tumors. 除了, they outline a process to test potential drugs to help prioritize clinical therapy choices based on unique tumor characteristics.
这项研究, published this week in the journal 自然癌症, creates a way for researchers to narrow the number of drugs that might be effective in each tumor based on its unique characteristics and its behavior in the laboratory models of the cancer. Using this resource, the researchers uncovered experimental and Food and Drug Administration-approved drugs with high efficacy against the models. They extended this work to personalize therapy for a patient with metastatic breast cancer, which resulted in a complete response for the patient and a progression-free survival period more than three times longer than her previous therapies.
"We were able to utilize the data to prioritize therapy options for a patient," says Alana Welm博士, 该研究, breast cancer researcher at Huntsman Cancer Institute, and professor of oncological sciences at the U of U. "While this therapy was unfortunately not curative, it led to regression of the patient’s tumor and a longer survival period."
Welm说 this unique bank of tumor models is critical to advancing research on aggressive breast cancers. 这也是, 据大发娱乐所知, the first time that such models have been used to influence the therapy choice of a breast cancer patient in a clinical trial setting."
The research team included a diverse group of clinicians, laboratory researchers, and technicians from Huntsman Cancer Institute at the 犹他大学, Baylor College of Medicine, 杰克逊实验室, the University of Connecticut, and the University of Pittsburgh. The team worked together to prioritize advancing research on samples most aligned with current challenges seen in the clinic.
A new clinical trial called FORESEE (NCT04450706) builds on the findings of this study. 由 桑德拉·拜斯，马里兰州, chief of the division of oncology at Huntsman Cancer Institute, the trial tests patient-derived tumor models to inform the treatment selection in metastatic breast cancer 病人.
With a second trial in development, Welm说, "We will also use the models to predict recurrence for a subset of newly diagnosed breast cancer 病人, and then attempt to personalize therapy for the metastatic stage of the disease when recurrence happens."
这项研究 was supported by the National Institutes of Health/National Cancer Institute including P30 CA042014 and Huntsman Cancer Foundation. The authors would like to thank the National Cancer Institute Moonshot PDX Network program, Huntsman Cancer Institute shared resources, and the U of U Flow Cytometry and Cell Imaging cores.
About Huntsman Cancer Institute at the 犹他大学
Huntsman Cancer Institute （HCI）在 犹他大学 is the official cancer center of Utah and the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West. The campus includes a state-of-the-art cancer specialty hospital, and two buildings dedicated to cancer research. HCI provides patient care, 癌症筛查, and education at community clinics and affiliate hospitals throughout the Mountain West. HCI is consistently recognized among the best cancer hospitals in the country by U.S. News and World Report. 该地区第一个 proton therapy center opened in 2021 and a major hospital expansion is underway. HCI is committed to creating a diverse and inclusive environment for staff, 学生, 病人, 和社区. Advancing cancer research discoveries and treatments to meet the needs of 病人 who live far away from a major medical center is a unique focus. More genes for inherited cancers have been discovered at HCI than at any other cancer center, including genes responsible for breast, 卵巢, 结肠, head and neck cancers, 和黑素瘤. HCI是由 乔恩·米. 和卡伦·亨茨曼.